Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

NCT02783040 PHASE1 COMPLETED Results posted

To assess the influence of multiple doses of BI 425809 on single dose pharmacokinetics of midazolam (CYP3A4 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug) and digoxin (P-gp probe drug)

Details

Lead sponsor	Boehringer Ingelheim
Phase	PHASE1
Status	COMPLETED
Enrolment	13
Start date	Mon Sep 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Oct 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy

Interventions

• Midazolam
• Warfarin
• Omeprazole
• Digoxin
• BI 425809

Countries

Germany